Eton Pharmaceuticals (ETON) announced that the United States Patent and Trademark Office has granted the company U.S. Patent No. 12,214,010, covering its ET-600 product candidate’s proprietary formulation of desmopressin oral solution. The patent expires in 2044 and is expected to be listed in the FDA Orange Book upon the product’s approval. The company has an additional patent application related to the product under review with the USPTO. ET-600 previously passed a pilot bioequivalence study in 2024 and is currently undergoing its pivotal bioequivalence study. The company expects to have study results at the end of February. If results are positive, the company anticipates filing a New Drug Application with the FDA for the product by the second quarter of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Eton Pharmaceuticals: FDA extends PDUFA date for NDA for ET-400 to 5/28
- Eton Pharmaceuticals price target raised to $23 from $18 at Craig-Hallum
- Eton Pharmaceuticals price target raised to $33 from $17 at H.C. Wainwright
- Eton Pharmaceuticals initiated with a Buy at B. Riley
- Eton Pharmaceuticals price target raised to $18 from $15 at Craig-Hallum